Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 12, 2025 to...

Key Takeaway: Alkermes plc will host a conference call on February 12, 2025, to discuss its fourth quarter and year-end 2024 financial results. The management will also outline financial expectations for 2025 and provide updates on the company's operations. Investors can access the call via phone or webcast, with a replay available afterward.
Price reaction · baseline $31.3 (2025-02-04 close) · hit after-hours · clean, no other ALKS news in the window
day 0 close · peak
+0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Alkermes will discuss financial expectations for 2025.
  • The company is committed to innovative medicines in neuroscience.
  • The upcoming conference call provides transparency to investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
3.3%
average across 7 past catalysts
Lead asset
N1539
Phase 2 · Hysterectomy

Full Press Release Details

DUBLIN , Feb. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS ) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. GMT ) on Wednesday, Feb. 12, 2025 to discuss the company's fourth quarter and year-end 2024 financial results. Management will also discuss financial expectations for 2025 and provide an update on the company.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com . The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.
About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland , Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio . For more information, please visit Alkermes' website at www.alkermes.com .

Frequently Asked Questions

When will Alkermes report its financial results?

Alkermes will report its financial results on February 12, 2025.

How can I access the Alkermes conference call?

The conference call can be accessed by dialing +1 877 407 2988 for U.S. callers.

What will be discussed during the call?

The call will cover Q4 and year-end 2024 financial results and 2025 expectations.

Is there a replay available for the conference call?

Yes, a replay will be available approximately two hours after the event.

Last updated: Feb 5, 2025